Adeno-associated viruses (AAVs) have emerged in recent years as a crucial tool in clinical gene therapies, offering low pathogenicity and long-lived gene expression in target cells. AAVs are simple ...

The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...